Berberine: A Promising Natural Isoquinoline Alkaloid for the Development of Hypolipidemic Drugs

被引：38
作者：
Li, Dong-Dong [1 ,2 ]
Yu, Pan [1 ,2 ]
Xiao, Wei [3 ]
Wang, Zhen-Zhong [3 ]
Zhao, Lin-Guo [1 ,2 ]
机构：
[1] Nanjing Forestry Univ, Jiangsu Coinnovat Ctr Efficient Proc & Utilizat F, Nanjing 210037, Peoples R China
[2] Nanjing Forestry Univ, Coll Chem Engn, 159 Long Pan Rd, Nanjing 210037, Peoples R China
[3] Jiangsu Kanion Pharmaceut Co Ltd, 58 Haichang South Rd, Lianyungang 222001, Peoples R China
来源：
CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2020年 / 20卷 / 28期
关键词：
Berberine; Hypolipidemic activity; Physicochemical property; Cholesterol; Triglyceride; Bioavailability; Chemical modification; DENSITY-LIPOPROTEIN RECEPTOR; TYPE-2; DIABETES-MELLITUS; BILE-ACID METABOLISM; LDLR UP-REGULATION; GUT MICROBIOTA; MESSENGER-RNA; BERBERRUBINE DERIVATIVES; ANTIMICROBIAL ACTIVITY; INSULIN-RESISTANCE; LIPID-ACCUMULATION;
D O I：
10.2174/1568026620666200908165913
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Berberine, as a representative isoquinoline alkaloid, exhibits significant hypolipidemic activity in both animal models and clinical trials. Recently, a large number of studies on the lipid-lowering mechanism of berberine and studies for improving its bypolipidemic activity have been reported, but for the most part, they have been either incomplete or not comprehensive. In addition, there have been a few specific reviews on the lipid-reducing effect of berberine. In this paper, the physicochemical properties, the lipid-lowering mechanism, and studies of the modification of berberine all are discussed to promote the development of berberine as a lipid-lowering agent. Subsequently, this paper provides some insights into the deficiencies of berberine in the study of lipid-lowering drug, and based on the situation, some proposals are put forward.
引用
收藏
页码：2634 / 2647
页数：14
相关论文
共 150 条
[1]   Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine [J].
Abidi, P ;
Zhou, Y ;
Jiang, JD ;
Liu, JW .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (10) :2170-2176
[2]   Crystal engineering of the composition of pharmaceutical phases.: Do pharmaceutical co-crystals represent a new path to improved medicines? [J].
Almarsson, Ö ;
Zaworotko, MJ .
CHEMICAL COMMUNICATIONS, 2004, (17) :1889-1896
[3]  
[Anonymous], 2013, MED CHEM LETT, DOI DOI 10.1016/J.BMC1.2012.10.098
[4]  
[Anonymous], 2009, PHOTOCH PHOTOBIO SCI, DOI DOI 10.1039/b822363g
[5]  
[Anonymous], 2020, MOLECULES, DOI DOI 10.3390/M0LECULES25081957
[6]  
[Anonymous], 2018, POLYMERS-BASEL, DOI DOI 10.3390/P0LYML
[7]  
Avdeef Alex, 2001, Current Topics in Medicinal Chemistry, V1, P277, DOI 10.2174/1568026013395100
[8]   Physicochemical Characterization of Berberine Chloride: A Perspective in the Development of a Solution Dosage Form for Oral Delivery [J].
Battu, Sunil Kumar ;
Repka, Michael A. ;
Maddineni, Sindhuri ;
Chittiboyina, Amar G. ;
Avery, Mitchell A. ;
Majumdar, Soumyajit .
AAPS PHARMSCITECH, 2010, 11 (03) :1466-1475
[9]   A conserved role for cytoplasmic poly(A)-binding protein 1 (PABPC1) in nonsense-mediated mRNA decay [J].
Behm-Ansmant, Isabelle ;
Gatfield, David ;
Rehwinkel, Jan ;
Hilgers, Valerie ;
Izaurralde, Elisa .
EMBO JOURNAL, 2007, 26 (06) :1591-1601
[10]   Berberine Effects on NFκB, HIF1A and NFE2L2/AP-1 Pathways in HeLa Cells [J].
Belanova, Anna ;
Beseda, Darya ;
Chmykhalo, Victor ;
Stepanova, Alisa ;
Belousova, Mariya ;
Khrenkova, Vera ;
Gavalas, Nikolaos ;
Zolotukhin, Peter .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (04) :487-501
12345678910